Artrya Ltd
Artrya Limited is a medical technology company.
The business
Artrya Limited is a medical technology company. The Company is developing artificial intelligence (AI) powered solutions to improve the detection and management of coronary artery disease. It is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop an overview of a patient at risk. The company has developed deep learning algorithms that allow for the prediction and prevention of acute coronary events. Its Artrya Salix is a computed tomography coronary angiography (CCTA) image analysis solution that enables physicians with AI to identify and analyze the extent and type of arterial plaque. This solution uses no external reading teams to validate cardiac scan data, allowing physicians direct control of their AI-supported patient scans. Artrya Salix provides solutions for physicians and patients.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Artrya Secures Second US Commercial Order for Salix SaaS Platform to Manage Coronary Artery Disease
Artrya (ASX: AYA) has signed a commercial agreement with US-based Northeast Georgia Health System for the use of its Salix AI cloud platform for point-of-care assessment and management of coronary artery disease.
Artrya Wins FDA Clearance to Advance Rollout of Salix Coronary Plaque Module
Artrya (ASX: AYA) has received clearance from the US Food and Drug Administration for its Salix Coronary Plaque module. The regulatory milestone enables the company to charge per-scan fees in its largest market, significantly enhancing revenue potential. The approval follows Artrya’s recent US launch and builds on momentum established with its Salix Coronary Anatomy platform. […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.